当前位置:主页 > 医学论文 > 精神病论文 >

大鼠脑组织中甲状腺素受体THRα1的表达与阿尔茨海默病发病机制的实验研究

发布时间:2018-04-17 18:20

  本文选题:甲状腺素受体α1 + 阿尔茨海默病 ; 参考:《兰州大学》2012年硕士论文


【摘要】:目的:复制阿尔茨海默病动物模型,观察其大脑皮层和海马区脑组织中甲状腺素受体THR α1的表达与阿尔茨海默病发生的相关性,并从THRα1表达增加对神经细胞tau蛋白磷酸化影响的角度对其机制进行初步探讨。 方法:SD大鼠腹腔注射D-半乳糖50mg·kg-1·d-1,复制阿尔茨海默病动物模型,另设正常对照组,腹腔注射等量生理盐水。连续给药6w后观察观察动物一般情况如精神状态、活动情况、皮毛等;经二次固定法固定后取全脑组织制作病理切片,进行HE染色和改良Bicschowsky染色,用以观察大脑皮层及海马组织中老年斑,神经元纤维缠结及神经元数量、体积、排列状况等形态学变化;分别用实时荧光定量PCR (Real time fluorescence quantitation PCR, FQ-PCR)法和Western blot法检测阿尔茨海默病动物与正常大鼠脑组织中THRα1、CDK-5及p35mRNA的差异性表达和pser404-tau蛋白的表达水平。 结果:与正常对照组相比,阿尔茨海默病模型组动物神情呆滞,反应迟钝,撮毛等;镜下见大脑皮层及海马区神经元排列紊乱、层次减少,核呈固缩、深染状,神经元轴突染色较深呈拖尾状,形成神经元纤维缠结,尤以海马区表现更为显著。与对照组相比,模型组皮层区THRα1、CDK-5和p35mRNA表达量增加,分别为1.20±0.30、4.71±0.54、2.11±0.40,差异有统计学意义(P0.05);模型组海马区三者的表达量分别为2.53±0.65、18.51±2.77、5.96±0.49,与对照组相比亦有统计学差异(P0.05)模型组pser404-tau蛋白呈高表达状态,与正常对照组相比P0.05。 结论:阿尔茨海默病动物大脑皮层及海马区神经细胞中THRα1mRNA的表达量显著高于正常对照组大鼠,过高THRα1可提高tau蛋白磷酸化相关激酶CDK-5mRNA及其调节因子p35mRNA的表达水平,进而加剧神经细胞tau蛋白磷酸化,导致动物大脑皮层及海马区出现神经元丢失、神经纤维缠结等典型的AD形态学变化,这可能是THRα1过表达导致阿尔茨海默病发生的主要机制之一。
[Abstract]:Objective: to study the relationship between the expression of thyroxine receptor THR 伪 1 in cerebral cortex and hippocampus and the occurrence of Alzheimer's disease.The effect of THR 伪 1 expression on the phosphorylation of tau protein in nerve cells was also discussed.Methods Dgalactose 50mg kg-1 d-1 was injected intraperitoneally to make Alzheimer's disease animal model. The normal control group was set up and the same amount of normal saline was injected intraperitoneally.After 6 weeks of continuous administration, the general conditions of animals, such as mental state, activity, fur and so on, were observed, and the whole brain tissue was fixed by two fixation methods to make pathological sections for HE staining and modified Bicschowsky staining.To observe the morphological changes of senile plaques, the number, volume and arrangement of neurons in cerebral cortex and hippocampal tissue.Real time fluorescence quantitation PCR (FQ-PCR) and Western blot were used to detect the differential expression of THR 伪 1 CDK-5 and p35mRNA and the expression of pser404-tau protein in brain tissue of Alzheimer's disease and normal rats, respectively.Results: compared with the normal control group, the Alzheimer's disease model group showed dull expression, slow response, hair and so on, and the neurons of cerebral cortex and hippocampus were disordered, the layers decreased, the nucleus was pyknotic, deep stained, and so on.The axon staining of the neurons was deeply trailing, forming the neuronal fibrillary tangles, especially in the hippocampal area.Compared with the control group, the expression of THR 伪 1, CDK-5 and p35mRNA in the cortical area of the model group was increased.The expression of pser404-tau protein in the hippocampal area of the model group was 2.53 卤0.65 卤2.775 卤0.49, respectively, which was significantly higher than that in the control group (P 0.05) and the expression of pser404-tau protein in the model group was significantly higher than that in the normal control group (P 0.05). The expression of pser404-tau protein in the model group was significantly higher than that in the control group (P 0.05), and that in the hippocampal area of the model group was 2.53 卤0.65 卤2.775 卤0.49, which was also significantly higher than that in the control group (P 0.05).Conclusion: the expression of THR 伪 1mRNA in cerebral cortex and hippocampal neurons of Alzheimer's disease rats is significantly higher than that in normal control rats. Excessive THR 伪 1 can increase the expression of tau protein phosphorylated kinase CDK-5mRNA and its regulatory factor p35mRNA.In turn, the phosphorylation of tau protein in nerve cells is aggravated, resulting in the loss of neurons and neuronal tangles in the cortex and hippocampus of animals, and typical AD morphological changes, such as neurofibrillary tangles, and so on.This may be one of the main mechanisms of overexpression of THR 伪 1 leading to Alzheimer's disease.
【学位授予单位】:兰州大学
【学位级别】:硕士
【学位授予年份】:2012
【分类号】:R749.16

【相似文献】

相关期刊论文 前10条

1 ;世界新药之窗[J];中国新药杂志;2011年12期

2 ;阿尔茨海默病诊断标准更新[J];浙江中西医结合杂志;2011年07期

3 窦丽波;;阿尔茨海默病的住院护理[J];吉林医学;2011年26期

4 盛树力;;表观遗传学与阿尔茨海默病研究趋势[J];中国神经免疫学和神经病学杂志;2010年06期

5 刘建平;郭蕾;;阿尔茨海默病证候要素研究[J];中西医结合心脑血管病杂志;2011年07期

6 张君嗣;杨卓;;阿尔茨海默病Aβ大鼠模型颈上交感神经节神经传导和突触可塑性的损伤[J];天津医药;2011年07期

7 盖尔;庄稼英;;糖尿病和脑病[J];糖尿病天地(临床);2011年06期

8 董浩然;;降压药有助于避免老年性痴呆症[J];心血管病防治知识;2007年12期

9 黄延红;王俊杰;;阿尔茨海默病的发病机制及治疗[J];济宁医学院学报;2011年03期

10 彭素英;许之驹;李素君;吴燕明;;阿尔茨海默病30例护理效果分析[J];中国民康医学;2011年12期

相关会议论文 前10条

1 陈霞平;涂自良;杜士明;王启斌;张澈;张蓬华;;阿尔茨海默病的药物治疗进展[A];湖北省药学会第十一届会员代表大会暨2007年学术年会论文汇编[C];2007年

2 满永;夏永静;王抒;;载脂蛋白A-Ⅳ基因360位点与阿尔茨海默病和帕金森病的关系[A];中国病理生理学会动脉粥样硬化专业委员会五届一次会议论文集[C];2002年

3 王乃东;赵永波;;阿尔茨海默病的免疫治疗[A];中华医学会第七次全国神经病学学术会议论文汇编[C];2004年

4 施海姗;侯乐;宁玉萍;郑东;钟笑梅;;不同认知障碍的阿尔茨海默病患者睡眠特点分析[A];中华医学会精神病学分会第九次全国学术会议论文集[C];2011年

5 金元;曹红;葛仁山;;Nestorone和黄体酮对阿尔茨海默病大鼠记忆的影响及机制[A];2009年浙江省麻醉学学术会议论文汇编[C];2009年

6 庞丽;姚建莉;李海红;曹震;徐志峰;尤克增;陈耀文;吴仁华;;9.4T离体型核磁共振频谱对阿尔茨海默病海马谷氨酸变化的研究[A];中华医学会第16次全国放射学学术大会论文汇编[C];2009年

7 潘小玲;王刚;崔佩菁;王瑛;马建芳;任汝静;邓钰蕾;徐玮;汤荟冬;陈生弟;;GAB2基因多态性与阿尔茨海默病的相关性研究[A];中华医学会第十三次全国神经病学学术会议论文汇编[C];2010年

8 丛琳;;调控ADAM9基因表达的启动子区多态性对散发性阿尔茨海默病的保护作用[A];2011全国老年痴呆与衰老相关疾病学术会议第三届山东省神经内科医师(学术)论坛论文汇编[C];2011年

9 郭U,

本文编号:1764733


资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/jsb/1764733.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户2be43***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com